Posted on September 23rd, 2021. Posted by ICR Westwicke
The biotech market has been growing rapidly over the past two decades, and is expected to be worth nearly $2.5 trillion by 2028. Meanwhile, the pace of technological developments and innovation have reduced barriers to entry, leading to an influx of aspiring biotech startups eager to bring their products to market. But despite the increase in available capital, early-stage biotech companies are battling harder for their share of funding. In this article, we explore the challenges, strategies, and best practices in early-stage biotech funding.
Continue Reading
Posted on August 24th, 2021. Posted by ICR Westwicke
Just as schools and businesses run occasional fire drills, your company should periodically pressure test your crisis communications plan. To truly understand if and how the plan will work, your management team and employees need to see how your strategy will play out in a realistic scenario.
Continue Reading
Posted on August 10th, 2021. Posted by ICR Westwicke
It’s fair to believe that your business’s strategy and your leadership team’s ability to execute that plan will dictate your fate with investors. More often, however, it’s how those strategies and results are communicated — especially within the investor presentation — that have the most impact on a company’s credibility.
Continue Reading
Posted on August 3rd, 2021. Posted by ICR Westwicke
Whether for a one-on-one at a conference or an IPO road show, your corporate presentation is a critical piece of your investor relations strategy. A PowerPoint deck may seem trivial compared to the entirety of your enterprise, but the investor presentation remains one of the most tangible and effective tools for building (and losing) investor trust and engagement.
Continue Reading
Posted on July 22nd, 2021. Posted by ICR Westwicke
No matter how careful you are as a company, you can quickly find yourself in the center of a crisis you didn’t expect. When that crisis disrupts operations or threatens the reputation of the company, you must act swiftly but carefully.
Continue Reading
Posted on July 8th, 2021. Posted by ICR Westwicke
What is an 8-K?
Form 8-K, also known as an 8K, is a form that is filed by public companies to notify their shareholders and the Securities and Exchange Commission (SEC) when an unscheduled material event takes place. In other words, it’s an announcement that a major event or corporate change that may be of interest to investors, has occurred. Form 8K is known as a “current report” and is filed in addition to an annual report on Form 10-K and a quarterly report on Form 10-Q.
Continue Reading
Posted on June 21st, 2021. Posted by ICR Westwicke
There’s a saying in investor relations: “You date your investment bankers, but you marry your research analysts.” Essentially, this means that a sell side analyst who covers your company will remain your partner for the long run. Investment bankers, on the other hand, work with a long list of companies and deal with jam-packed, demanding schedules. They don’t disappear after the initial public offering (IPO), but the time they can devote to your company diminishes.
Continue Reading
Posted on May 20th, 2021. Posted by ICR Westwicke
Special purpose acquisition company (SPAC) activity has exploded in the past two years, from 59 transactions in 2019, to 248 deals in 2020, to 308 SPACs so far in 2021. However, SPACs are not new. This type of transaction has been around for decades, continually evolving as it rises and falls in popularity.
Continue Reading
Posted on April 22nd, 2021. Posted by ICR Westwicke
Unlike quiet periods following an IPO, which are closely regulated by the Securities and Exchange Commission (SEC), end-of-quarter quiet periods are more loosely defined and not strictly regulated.
Continue Reading
Posted on March 4th, 2021. Posted by ICR Westwicke
One of our clients, a recently public diagnostics company, settled an ongoing royalty dispute with a major pharmaceutical company. The settlement amount was significantly lower than what our client had accrued, resulting in nearly $750 thousand upside to their P&L in the upcoming quarter.
Continue Reading
